Table 4.

Major bleeding rates with apixaban or warfarin according to use of interacting drugs by ARISTOTLE trial participants

Interacting drugs	Use of potentiating drug (rate per 100 patient years (no of patients))			No use of potentiating drug (rate per 100 patient years (no of patients))		Pinteraction
	Apixaban	Warfarin		Apixaban	Warfarin
≥ 1 combined P-glycoprotein and weak/moderate/strong CYP3A4 inhibitor	2.27 (72)	2.91 (93)		2.10 (255)	3.14 (369)	0.39
≥1 highly probable VKA potentiating drug	2.03 (62)	3.16 (96)		2.16 (265)	3.07 (366)	0.64

CYP=cytochrome P450; VKA=vitamin K antagonist.